High dimensional digital pathology to investigate the tumor micro environment and its impact on response to therapy

NIH RePORTER · NIH · R50 · $215,543 · view on reporter.nih.gov ↗

Abstract

Summary Grant: Research Specialist (PAR-19-291) Under the supervision of senior scientist Zoltan Maliga PhD, investigators and staff at the Harvard Medical School Laboratory of Systems Pharmacology (LSP) will contribute to cell and tissue imaging and analysis for U2C and U54 program grants LSP-based investigators will perform the tissue-based cyclic immunofluorescence (t-CyCIF) method developed at HMS on FFPE human and mouse skin samples provided by investigators and will work together to define and validate antibodies to stain biomarkers of skin development, inflammation, melanoma progression and tumor microenvironment and will share technologies under development to further advance the t-CyCIF method (e.g. switch to six-channel imaging, use of oligo-modified antibodies as detection reagents, combination of in situ hybridization or sequencing methods). The LSP will process t-CyCIF images, provide quantitative cell and tissue-level analysis and help distribute high-resolution multiplexed images as part of a disease pathology atlas. Maliga will work with PIs Lian, Murphy, LeBoeuf, Haigis, Aster to prepare manuscripts, write reports for the NIH and collaborate with other members of the project teams as required the by PAR-19-291.

Key facts

NIH application ID
10246402
Project number
5R50CA252138-02
Recipient
HARVARD MEDICAL SCHOOL
Principal Investigator
Zoltan Maliga
Activity code
R50
Funding institute
NIH
Fiscal year
2021
Award amount
$215,543
Award type
5
Project period
2020-09-01 → 2025-08-31